{"title":"新型干粉吸入器。","authors":"Andrzej Emeryk, Michał Pirożyński","doi":"10.5603/PiAP.2015.0012","DOIUrl":null,"url":null,"abstract":"<p><p>The most recently approved DPI's - Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD. </p>","PeriodicalId":20258,"journal":{"name":"Pneumonologia i alergologia polska","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"[New dry powder inhalers].\",\"authors\":\"Andrzej Emeryk, Michał Pirożyński\",\"doi\":\"10.5603/PiAP.2015.0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The most recently approved DPI's - Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD. </p>\",\"PeriodicalId\":20258,\"journal\":{\"name\":\"Pneumonologia i alergologia polska\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pneumonologia i alergologia polska\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/PiAP.2015.0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumonologia i alergologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/PiAP.2015.0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The most recently approved DPI's - Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
